Diabetic Eye Disease



Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)


Condition:   Diabetic Retinopathy
Intervention:   Diagnostic Test: hematological examination, ophthalmic examination
Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not yet recruiting


Medico-economic Comparison Between Treatment With Panretinal Photocoagulation by Laser in 1 Session Versus 4 Sessions in Diabetic Retinopathy


Condition:   Diabetic Retinopathy
Interventions:   Procedure: monospot panretinal photocoagulation;   Procedure: multispot panretinal photocoagulation
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting


A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.


Condition:   Diabetic Retinopathy
Interventions:   Drug: BI 1467335;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting


The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)


Condition:   Nonproliferative Diabetic Retinopathy
Interventions:   Drug: AKB-9778;   Drug: Placebo
Sponsor:   Aerpio Therapeutics
Recruiting


Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool


Condition:   Diabetic Retinopathy
Interventions:   Procedure: Color fundus photography;   Drug: Mydriatic Agent
Sponsors:   Eyenuk, Inc.;   National Eye Institute (NEI)
Enrolling by invitation


Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes


Condition:   Diabetic Retinopathy
Intervention:  
Sponsor:   Association for Innovation and Biomedical Research on Light and Image
Recruiting


The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy


Condition:   Diabetic Retinopathy
Intervention:   Drug: Intravitreal Aflibercept injection
Sponsor:   Asan Medical Center
Recruiting


A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy


Condition:   Diabetic Retinopathy
Intervention:  
Sponsors:   IDx LLC;   The EMMES Corporation
Enrolling by invitation


Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Interventions:   Drug: intravitreal injection of conbercept;   Device: PRP
Sponsor:   Sun Yat-sen University
Enrolling by invitation


Genetic Markers and Proliferative Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Intervention:   Genetic: genetic analysis
Sponsor:   CHU de Reims
Recruiting


Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Intervention:   Drug: Aflibercept
Sponsors:   Charles C Wykoff, PhD, MD;   Regeneron Pharmaceuticals
Active, not recruiting


Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Interventions:   Drug: ranibizumab;   Drug: sham;   Procedure: pars plana vitrectomy
Sponsor:   Sun Yat-sen University
Completed


Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Interventions:   Drug: emixustat hydrochloride;   Other: Placebo
Sponsor:   Acucela Inc.
Recruiting


Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)


Condition:   Nonproliferative Diabetic Retinopathy
Interventions:   Drug: Intravitreal aflibercept injection [IAI];   Drug: Sham
Sponsor:   Regeneron Pharmaceuticals
Active, not recruiting


Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy


Condition:   Non-proliferative Diabetic Retinopathy
Interventions:   Drug: Compound danshen dripping pills;   Drug: Placebo
Sponsor:   Tasly Pharmaceuticals, Inc.
Active, not recruiting


Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia


Condition:   Diabetic Retinopathy
Intervention:   Other: Initiation of treatment of diabetes
Sponsor:   Temple University
Recruiting


Collaborative Care for Depression and Diabetic Retinopathy in African Americans


Condition:   Diabetic Retinopathy
Intervention:   Behavioral: Behavioral Activation
Sponsors:   Thomas Jefferson University;   Wills Eye
Active, not recruiting


Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery


Condition:   Diabetic Retinopathy
Interventions:   Drug: Aflibercept;   Drug: Sham
Sponsors:   Rishi Singh;   Regeneron Pharmaceuticals
Recruiting


RETeval Study for Diabetic Retinopathy


Condition:   Diabetic Retinopathy
Intervention:   Device: RETeval
Sponsors:   Inoveon Corporation;   LKC Technologies, Inc.;   National Eye Institute (NEI)
Completed


Computer-based Screening for Diabetic Retinopathy


Condition:   Diabetic Retinopathy
Intervention:  
Sponsors:   VisionQuest Biomedical LLC;   Project Extension for Community Healthcare Outcomes (ECHO);   Communicare Health Centers of San Antonio;   Retinal Institute of South Texas;   National Eye Institute (NEI)
Completed


Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)


Condition:   Proliferative Diabetic Retinopathy (PDR)
Interventions:   Drug: Ranibizumab;   Procedure: Laser photocoagulation;   Procedure: Ranibizumab & laser photocoagulation
Sponsors:   Novartis Pharmaceuticals;   Cologne Image Reading Center & Laboratory (CIRCL);   Spranger Laboratories
Active, not recruiting


Propranolol for Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Intervention:   Drug: Propranolol
Sponsor:   University of Wisconsin, Madison
Completed


Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy


Condition:   Proliferative Diabetic Retinopathy
Interventions:   Other: Prompt Panretinal Photocoagulation;   Drug: 0.5-mg Ranibizumab;   Other: Deferred panretinal photocoagulation
Sponsors:   Jaeb Center for Health Research;   National Eye Institute (NEI);   Genentech, Inc.
Active, not recruiting


Avastin for PDR (Proliferative Diabetic Retinopathy)


Conditions:   Retinal Detachment;   Diabetic Retinopathy
Interventions:   Drug: Avastin (bevacizumab);   Other: Sham injection
Sponsor:   University of Southern California
Completed


Blood Factors and Diabetic Retinopathy


Condition:   Diabetic Retinopathy
Intervention:  
Sponsor:   National Eye Institute (NEI)
Completed

Refine Your Search Advanced Search